Longeveron Inc. (LGVN)
After hours:
- GlobeNewswire
Longeveron Announces Board of Directors Planned Transitions
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron BoardDr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company’s Annual Meeting of StockholdersNeha Motwani, former managing director and senior healthcare investment banker at William Blair, Truist, and Oppenheimer and Company, also has been nominated as a candidate for the Boa
- GlobeNewswire
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET. Conference Call Details: Conference Call Number: 1.877.407.0789 Conference ID: 13745868 Call meTM Featur
- GlobeNewswire
Longeveron to Present at the Planet MicroCap Showcase
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s presentation: Date:Wednesday, May 1, 2024 Time:4:30 p.m. PT Webcast:Click Here An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference. If
